Zhejiang Otsuka Pharmaceutical
CompanyChina
Zhejiang Otsuka Pharmaceutical develops one asset, in phase 3 (Prusogliptin in type 2 diabetes). Mostly small molecule acting on DPP4; based in China.
- 1
- Asset
- Furthest stage
- Phase 3
- 23
- Trials
- 0
- Signals
Pipeline
1Dipeptidyl peptidase-4 (DPP-4) inhibitor improving glycemic control
Phase 3, Small molecule, DPP4, type 2 diabetes
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms2
- Trials36
- Signals1
- Similar companies6